USPTO published patent application US20260091060A1, filed by Ralf Holger Voss, Ugur Sahin, and colleagues, covering recombinant antigen receptors and T cells engineered to express such receptors for disease treatment. The application (No. 18905085) claims compositions and methods involving antigen receptors targeting cells expressing specific surface antigens. The invention spans multiple CPC classifications including C07K 14/7051 (amino acid sequences), C12N 5/0636 (cell therapy), and A61K 35/17 (T cell preparations).

Patent applications are informational publications that do not create compliance obligations or deadlines for regulated entities. Companies developing cell therapy or CAR-T products may wish to review the claims for potential freedom-to-operate implications or licensing considerations. The application is currently pending examination and has not yet matured into an issued patent.